Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B-Reference-Cited by-同舟云学术

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Published:2016-09 Issue:3 Volume:65 Page:509-516
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Lok Anna S.,Pan Calvin Q.,Han Steven-Huy B.,Trinh Huy N.,Fessel W. Jeffrey,Rodell Timothy,Massetto Benedetta,Lin Lanjia,Gaggar Anuj,Subramanian G. Mani,McHutchison John G.,Ferrari Carlo,Lee Hannah,Gordon Stuart C.,Gane Edward J.

Publisher

Elsevier BV

Subject

Hepatology

Reference29 articles.

1. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013;Schweitzer;Lancet,2015

2. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures;Lavanchy;J Viral Hepat,2004

3. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B;Marcellin;N Engl J Med,2004

4. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B;Marcellin;N Engl J Med,2008

5. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection;J Hepatol,2012

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B;Annals of Hepatology;2025-01

2. Evolution and diversity of the hepatitis B virus genome: Clinical implications;Virology;2024-10

3. Efficacy and safety of therapeutic vaccines for the treatment of chronic hepatitis B: A systematic review and meta-analysis of randomized controlled trials update;Medicine;2024-08-30

4. Harnessing CD8⁺ T cell dynamics in hepatitis B virus‐associated liver diseases: Insights, therapies and future directions;Clinical and Translational Medicine;2024-06-27

5. High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy;Gut;2024-06-20